SCHEDULE: Biotechnology Value Fund Boosts Verastem Stake
Beneficial Ownership Report
Biotechnology Value Fund and its affiliates reported a combined beneficial ownership of 9.99% in Verastem, Inc. common stock as of June 30, 2025.
Summary
- Biotechnology Value Fund, L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in Verastem, Inc.
- As of June 30, 2025, the aggregate beneficial ownership by BVF Partners L.P., BVF Inc., and Mark N. Lampert was 5,720,831 shares, representing approximately 9.99% of the outstanding common stock.
- This percentage is calculated based on 54,949,170 shares outstanding as of May 12, 2025, plus certain exercisable warrants.
- The reporting persons and a Partners managed account held an aggregate of 2,500,000 warrants, exercisable for 2,500,000 shares at an exercise price of $3.50 per share, valid for 18 months from issuance.
- A 'Warrants Blocker' limits the exercise of these warrants such that beneficial ownership does not exceed 9.99% of outstanding shares or combined voting power. As of June 30, 2025, this blocker limited exercisable warrants to 2,316,406 shares out of the total 2,500,000 underlying warrants.
- Specifically, BVF beneficially owned 3,244,310 shares (5.8%), including 1,396,290 shares underlying warrants.
- BVF2 beneficially owned 2,173,798 shares (3.9%), including 920,116 shares underlying warrants.
- Biotechnology Value Trading Fund OS LP beneficially owned 214,663 shares (less than 1%), excluding 100,150 shares underlying warrants.
- BVF GP Holdings LLC was deemed to beneficially own 5,418,108 shares (9.5%), representing the aggregate of BVF and BVF2 holdings.
Sentiment
Score: 5
Explanation: This filing is a routine disclosure of beneficial ownership and does not contain performance or forward-looking statements, thus indicating a neutral sentiment.
Positives
- A significant institutional investor group maintains a substantial stake in Verastem, Inc., indicating continued interest in the company.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The filing details a group of related entities (Biotechnology Value Fund, L.P., BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert) that collectively hold and manage the beneficial ownership in Verastem, Inc. Mark N. Lampert is identified as a director and officer of BVF Inc., which is the general partner of BVF Partners L.P., the investment manager for several of the funds.
Key Dates
| Date | Description |
|---|---|
| 05/12/2025 | Date of disclosure for 54,949,170 shares outstanding in the Issuer's Prospectus. |
| 06/30/2025 | Date of event which requires filing of this statement, reflecting the reported beneficial ownership. |
| 08/13/2025 | Date the Schedule 13G Amendment No. 9 was signed. |
Keywords
Verastem, Biotechnology Value Fund, BVF, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.